ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Lilly to spin off Elanco Animal Health in IPO

by Melody M. Bomgardner
July 27, 2018 | APPEARED IN VOLUME 96, ISSUE 31

 

09631-buscon12-cowscxd.jpg
Credit: Shutterstock
Elanco sells vaccines and drugs for cows and other livestock.

Following a study period, Eli Lilly & Co. has decided to spin off its Elanco Animal Health business in order to focus on human health. Elanco sells drugs and vaccines for livestock and pets. Lilly says it will file for an initial public stock offering of 20% of Elanco in the coming weeks. Pfizer made a similar move in 2013 when it spun off its Zoetis animal health business. In 2016, Sanofi also rid itself of its animal health business, Merial, by trading it for Boehringer Ingelheim’s consumer health care business.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment